Anzeige
Mehr »
Samstag, 23.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
553 Leser
Artikel bewerten:
(2)

Endoron Medical awarded a €2.5M grant from the European Commission through the prestigious EIC Accelerator Program

  • Endoron is one of 75 companies selected among nearly 1000 applicants by the European program EIC Accelerator
  • The funds will enable the company to accelerate the development of its unique endovascular fastening solution for a complete seal and stability of endografts used for the treatment of abdominal aortic aneurysms

TEL AVIV, ISRAEL / ACCESSWIRE / November 14, 2022 / Endoron Medical, ("Endoron"), a medical device company developing an innovative solution for endovascular repair of abdominal aortic aneurysms, announced today it has been awarded a €2.5 million grant by the European Commission (EC) under the highly selective EIC Accelerator program.

Sofinnova Partners, Monday, November 14, 2022, Press release picture

Endoron's technology, Aortoseal®, was developed to overcome the challenges associated with the sealing and fixation of endografts used for the minimally invasive repair of abdominal aortic aneurysms (AAA) in difficult aortal anatomies, avoiding highly invasive, high-mortality open surgery, which is still being used in such cases. Aortoseal® is meant to provide long-term durability to endovascular aneurysm repairs (EVAR), thanks to its unique stapling mechanism.

This grant will support the scale-up and clinical evaluation of the Aortoseal® implant, required to bring this unique technology to the 4 million patients diagnosed with AAA who could benefit from a minimally invasive treatment approach.

Ronit Harpaz, Co-Founder and Chief Executive Officer of Endoron, commented: "We are delighted that Endoron has been singled out by the European Commission after an extremely selective process. The support of the EIC program validates our technology and our approach, recognizing the strong value created and milestones achieved in the past 30 months. This grant will help accelerate the development and clinical validation of our Aortoseal® implant, enabling a maximum of patients suffering from AAA to benefit from this minimally invasive approach, which has the potential to become the new standard of care."

Endoron is one of the 75 companies to have been awarded funding during the latest round of the program, which had nearly 1000 candidates.

###

About the EIC Accelerator program
The EIC Accelerator program is part of the European Innovation Council (EIC) project, which sits within the European Union's €95 billion Horizon Europe framework program for research and innovation. The EIC Accelerator offers start-ups and SMEs grants of up to €2.5 million to help these companies develop and bring to market innovative products that can stimulate economic growth in Europe.

About Endoron Medical
Endoron Medical was created in 2019 by three founders with extensive industry expertise and entrepreneurial experience: Ronit Harpaz, a member of the Elite 8400 Network and former CEO of Bendit Technologies; Prof. Ron Karmeli, a world-renowned vascular surgeon who is Endoron's Chief Medical officer and the inventor of the technology; Eyal Teichman, Chief Technology Officer, a mechanical engineer with over 30 years of experience in research and development in the field. The company was seed financed in 2021 by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan.

For further information, visit endoronmedical.com

Contact:
Ronit Harpaz
Chief Executive Officer, Endoron Medical
Ronit@endoronmedical.com

SOURCE: Endoron Medical

View source version on accesswire.com:
https://www.accesswire.com/725528/Endoron-Medical-awarded-a-25M-grant-from-the-European-Commission-through-the-prestigious-EIC-Accelerator-Program

© 2022 ACCESS Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.